Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Is glaucoma an optinopathy?
Author Affiliations & Notes
  • Michael H Farkas
    Ophthalmology, University at Buffalo, Buffalo, New York, United States
  • Tadeusz Kaczynski
    Ophthalmology, University at Buffalo, Buffalo, New York, United States
  • Maria Sousa
    Ophthalmology, University at Buffalo, Buffalo, New York, United States
  • Elizabeth Au
    Ophthalmology, University at Buffalo, Buffalo, New York, United States
  • Margaret M Deangelis
    Ophthalmology, University at Buffalo, Buffalo, New York, United States
  • Footnotes
    Commercial Relationships   Michael Farkas None; Tadeusz Kaczynski None; Maria Sousa None; Elizabeth Au None; Margaret Deangelis None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 3580. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Michael H Farkas, Tadeusz Kaczynski, Maria Sousa, Elizabeth Au, Margaret M Deangelis; Is glaucoma an optinopathy?. Invest. Ophthalmol. Vis. Sci. 2024;65(7):3580.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Primary open angle glaucoma, regardless of IOP, leads to death of the retinal ganglion cells (RGCs), and ultimately, vision loss. The pathogenic mechanism of RGC loss is currently unknown. Herein, we investigated the role of oligomerization and aggregation of Optineurin (OPTN) in human donor tissue and in vitro cell culture.

Methods : We analyzed OPTN oligomerization following oxidative stress in induced pluripotent stem cell derived RGCs and evaluated autophagy as a proxy marker for OPTN function. Oxidative stress was performed by culturing cells at physiological oxygen (5% O2, normoxia) and atmospheric oxygen (20% O2, hyperoxia) in a Biospherix hypoxia chamber for two weeks. Further, we used siRNA-mediated knockdown of OPTN to determine if reduced levels effected function. Using Alpha Fold 2 we predicted the structure of OPTN and its oligomeric forms, to determine if oligomerization blocks protein binding domains important for ubiquitination and autophagy. Finally, we evaluated OPTN oligomerization in human donor retinas with and without primary open angle glaucoma by Western blot, and aggregation in RGCs using immunohistochemistry.

Results : Our results show that increased oxygen levels leads to a 100% increase in OPTN oligomerization. This leads to a 75% decrease in autophagy, as determined by LC3-II levels. Knockdown of OPTN using an siRNA approach resulted in 80% knockdown efficiency and a 150% decrease in autophagy. Alpha Fold 2 models of OPTN suggests that it is naturally a disordered protein composed of coiled regions. Upon oligomerization, the multiple OPTN proteins form a coiled-coil structure blocking most of the protein-binding domains. Western blot analysis of human POAG donor retina shows a 25-50% increase in oligomer formation with a 25-40% decrease in monomeric OPTN, relative to the age- and sex-matched normal controls. Further, immunohistochemistry reveals that OPTN has a diffuse cytoplasmic presence in normal human RGCs, suggesting monomeric OPTN, whereas the human POAG donors show aggregated OPTN with no diffuse staining.

Conclusions : OPTN oligomerization and aggregation has the potential to be a disease causing mechanism in primary open angle glaucoma, similar to other neuropathies such as Alzheimer’s, Parkinson’s, and Huntington’s Disease. Although more functional information is needed regarding this process, it provides a potential therapeutic target without regard to the mutational status of the patient.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×